SNORA63: A Potential Drug Target and Biomarker for Diseases (G6043)

Target Name: SNORA63

NCBI ID: G6043

SNORA63

SNORA63: A Potential Drug Target and Biomarker for Diseases

SNORA63 (RNE3) is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and expression patterns have made it an attractive target for researchers to study.

SNORA63 is a non-coding RNA molecule that contains 63 exons. It is located on chromosome 6q24 and has a length of approximately 200 nucleotides. SNORA63 is a transcribed RNA molecule that is expressed in various tissues and cells in the body. It is highly expressed in the brain and nervous system, and its expression level is also increased in certain diseases, such as Alzheimer's disease and Parkinson's disease.

The RNE3 gene has been studied extensively, and many researchers have identified its potential drug target properties. One of the main reasons for its potential as a drug target is its unique structure. SNORA63 has a unique five-end structure, which is rare in non-coding RNAs. This structure allows it to interact with other molecules in the body, including proteins, drugs, and small molecules.

Another reason for its potential as a drug target is its expression pattern in certain diseases. As mentioned earlier, SNORA63 is highly expressed in the brain and nervous system, and its expression level is also increased in certain diseases, such as Alzheimer's disease and Parkinson's disease. This suggests that it may play a role in the development and progression of these diseases. By targeting SNORA63, researchers may be able to develop new treatments for these diseases.

In addition to its potential drug target properties, SNORA63 has also been identified as a biomarker for various diseases. Its expression level is often used as a diagnostic marker for diseases of the brain and nervous system, such as Alzheimer's disease, Parkinson's disease, and other neurodegenerative diseases. This suggests that it may be a useful tool for the diagnosis and treatment of these diseases.

Another potential application of SNORA63 as a biomarker is its potential to predict the outcomes of certain diseases. By analyzing the expression level of SNORA63 in patient samples, researchers may be able to predict the response of these patients to certain treatments, which could be used to improve the effectiveness of these treatments.

In conclusion, SNORA63 is a gene that has shown promising potential as a drug target and biomarker for various diseases. Its unique structure and expression patterns make it an attractive target for researchers to study. Further research is needed to fully understand its potential as a drug and biomarker, and to develop new treatments for the diseases it is associated with.

Protein Name: Small Nucleolar RNA, H/ACA Box 63

The "SNORA63 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORA63 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets